XML 16 R6.htm IDEA: XBRL DOCUMENT v3.23.3
Consolidated Statements of Changes in Shareholders' Equity (Unaudited) - USD ($)
$ in Thousands
Total
Cumulative Effect, Period of Adoption, Adjustment
Common stock and additional paid-in capital
Retained earnings
Retained earnings
Cumulative Effect, Period of Adoption, Adjustment
Accumulated other comprehensive income (loss)
Beginning balance (in shares) at Dec. 31, 2021     10,998,765      
Balance at beginning of period at Dec. 31, 2021 $ 245,657   $ 66,940 $ 180,417   $ (1,700)
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
     Net income 29,793     29,793    
Net unrealized loss on securities available for sale, net of tax (45,943)         (45,943)
Net unrealized gain on securities transferred from available for sale to held to maturity, net of tax 20         20
Net unrealized gain on cash flow hedging derivative instruments, net of tax 500         500
Comprehensive income (loss) (15,630)     29,793   (45,423)
Cash dividends declared (11,032)     (11,032)    
Equity compensation expense 610   $ 610      
Payment to repurchase common stock (in shares)     (8,640)      
Payment to repurchase common stock (276)     (276)    
Issuance of restricted stock (in shares)     28,745      
Proceeds from sale of common stock (in shares)     19,354      
Proceeds from sale of common stock $ 588   $ 588      
Ending balance (in shares) at Sep. 30, 2022 11,038,224   11,038,224      
Balance at end of period at Sep. 30, 2022 $ 219,917   $ 68,138 198,902   (47,123)
Beginning balance (in shares) at Dec. 31, 2021     10,998,765      
Balance at beginning of period at Dec. 31, 2021 $ 245,657   $ 66,940 180,417   (1,700)
Ending balance (in shares) at Dec. 31, 2022 11,045,186   11,045,186      
Balance at end of period at Dec. 31, 2022 $ 228,923 $ (6,277) $ 68,545 204,343 $ (6,277) (43,965)
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Accounting Standards Update [Extensible List] Accounting Standards Update 2016-13 [Member]          
Beginning balance (in shares) at Jun. 30, 2022     11,030,236      
Balance at beginning of period at Jun. 30, 2022 $ 227,685   $ 67,737 192,565   (32,617)
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
     Net income 10,091     10,091    
Net unrealized loss on securities available for sale, net of tax (14,866)         (14,866)
Net unrealized gain on securities transferred from available for sale to held to maturity, net of tax 6         6
Net unrealized gain on cash flow hedging derivative instruments, net of tax 354         354
Comprehensive income (loss) (4,415)     10,091   (14,506)
Cash dividends declared (3,754)     (3,754)    
Equity compensation expense 198   $ 198      
Issuance of restricted stock (in shares)     1,250      
Proceeds from sale of common stock (in shares)     6,738      
Proceeds from sale of common stock $ 203   $ 203      
Ending balance (in shares) at Sep. 30, 2022 11,038,224   11,038,224      
Balance at end of period at Sep. 30, 2022 $ 219,917   $ 68,138 198,902   (47,123)
Beginning balance (in shares) at Dec. 31, 2022 11,045,186   11,045,186      
Balance at beginning of period at Dec. 31, 2022 $ 228,923 $ (6,277) $ 68,545 204,343 $ (6,277) (43,965)
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
     Net income 22,839     22,839    
Net unrealized loss on securities available for sale, net of tax (9,134)         (9,134)
Net unrealized gain on securities transferred from available for sale to held to maturity, net of tax 6         6
Net unrealized gain on cash flow hedging derivative instruments, net of tax 866         866
Comprehensive income (loss) 14,577     22,839   (8,262)
Cash dividends declared (11,525)     (11,525)    
Equity compensation expense 607   $ 607      
Payment to repurchase common stock (in shares)     (12,629)      
Payment to repurchase common stock (248)     (248)    
Issuance of restricted stock (in shares)     33,610      
Proceeds from sale of common stock (in shares)     23,123      
Proceeds from sale of common stock $ 608   $ 608      
Ending balance (in shares) at Sep. 30, 2023 11,089,290   11,089,290      
Balance at end of period at Sep. 30, 2023 $ 226,665   $ 69,760 209,132   (52,227)
Beginning balance (in shares) at Jun. 30, 2023     11,081,800      
Balance at beginning of period at Jun. 30, 2023 232,003   $ 69,351 205,539   (42,887)
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
     Net income 7,474     7,474    
Net unrealized loss on securities available for sale, net of tax (10,071)         (10,071)
Net unrealized gain on securities transferred from available for sale to held to maturity, net of tax 1         1
Net unrealized gain on cash flow hedging derivative instruments, net of tax 730         730
Comprehensive income (loss) (1,866)     7,474   (9,340)
Cash dividends declared (3,881)     (3,881)    
Equity compensation expense 210   $ 210      
Payment to repurchase common stock (in shares)     (250)      
Proceeds from sale of common stock (in shares)     7,740      
Proceeds from sale of common stock $ 199   $ 199      
Ending balance (in shares) at Sep. 30, 2023 11,089,290   11,089,290      
Balance at end of period at Sep. 30, 2023 $ 226,665   $ 69,760 $ 209,132   $ (52,227)